We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




A Compound in Beer May Prevent Prostate Cancer

By LabMedica International staff writers
Posted on 08 Jan 2010
New research is highly suggestive that xanthohumol, a compound in beer, may prevent prostate cancer. More...
Tests revealed that xanthohumol blocked a biologic pathway that allows prostate cancer to be triggered by the male hormone testosterone.

Xanthohumol is derived from hops and belongs to the group of flavonoids that are found in many plants, fruit, spices, and vegetables. Earlier studies have shown that xanthohumol blocks the action of estrogen by binding to its receptor, which may lead to prevention of breast cancer.

Because testosterone receptors act similarly to that of estrogen--by binding, then stimulating hormone-dependent effects, such as gene expression and cell growth--the researchers examined whether xanthohumol might not only block the effects of estrogen, but also of the male hormone androgen.

Dr. Clarissa Gerhauser, from the German Cancer Research Center (Heidelberg, Germany), and colleagues stimulated hormone-dependent prostate cancer cells with testosterone, which led to a massive secretion of prostate-specific antigen (PSA).

PSA is used for screening and early detection of prostate cancer in men. Cells were then treated with testosterone and xanthohumol and the effects were examined. "Xanthohumol prevented the receptor from translocating to the cell nucleus, thus inhibiting its potential to stimulate the secretion of PSA and other hormone-dependent effects,” Dr. Gerhauser said.

Molecular modeling results demonstrated that xanthohumol directly binds to the androgen receptor structure. The researchers suggest that this compound may have beneficial effects in animals--when they measured the antiandrogenic potential of xanthohumol in a rat model, they discovered that although xanthohumol was not able to prevent an increase in prostate weight after testosterone treatment, it could reduce testosterone-increased seminal vesicle weight.

"Although the prostate weights were not changed, xanthohumol still reduced the effects of hormone signaling, such as gene expression, measured in the prostate tissue,” concluded Dr. Gerhauser.

The findings were presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held in Houston, TX, USA, December 6-9, 2009.

Related Links:

German Cancer Research Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
HPV Test
Allplex HPV28 Detection
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.